Altimmune has a modest market cap but an incredibly promising GLP-1 drug.
Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.
Viking Therapeutics just might be an attractive acquisition target for Pfizer.
Viking could have a strong rival to Novo Nordisk's Wegovy and Ozempic and Lilly's Mounjaro in the making.
Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP
The stock recently fell around 25% for reasons that had nothing to do with its lead program.
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
Altimmune (ALT) reports positive interim analysis data from a phase II obesity study of pemvidutide. However, the stock dropped about 55% likely due to concerns regarding the high discontinuation rate....
It's not the end of the story for this once high-flying biotech stock.
Concerns about a tough financing environment weighed on clinical-stage biotech stocks this week.